Navigation Links
Temprian Therapeutics Finalist in Nature Merck Spinoff 2020 Competition
Date:7/2/2020

Temprian, a spinoff from Northwestern University, has a platform technology intended for the treatment of autoimmune diseases. Its lead indication is vitiligo. Vitiligo patients develop progressive depigmentation of the skin. There is no cure for vitiligo at this time.

While vitiligo is equally prevalent in all ethnic groups, it is most visible and impactful in people with darker skin tones. Comorbidities include alopecia areata, hypothyroid disease and depression. The disease can bring heavy emotional stress. Patients are routinely subject to discrimination and prejudice, affecting personal relationships and job opportunities.

Historically, treatments for diseases that disproportionately affect people of color have received little attention or resources essential to moving them forward. Temprian’s selection as a finalist for the Nature Spinoff Prize provides hope for securing finances needed for a clinical trial.

The 12 finalists represent companies from the United States, United Kingdom, Switzerland and Spain operating in such diverse fields as pharmaceuticals, predictive assays and medical devices.

Details of Temprian’s innovation are covered on the Nature website. The Spinoff Prize has been established by the journal Nature in partnership with Merck KGaA to showcase and celebrate global excellence in the commercialization of research through the creation of spinoff companies.

ABOUT Temprian Therapeutics Inc. The company is a spinoff from Northwestern University, established to develop DNA based treatments for autoimmune disease. Its lead indication is vitiligo. The Company has worked closely with the patient community in the development of a safe, non-invasive, market-oriented treatment for vitiligo. The HSP70-based drug is designed to temper autoimmunity, arrests the spread of the disease and trigger repigmentation.

ABOUT Nature, Merck KGaA and the Spinoff Prize 2020: The Spinoff Prize has been established by the journal Nature Research in partnership with Merck to showcase and celebrate global excellence in the commercialization of research through the creation of spinoff companies.

IP: The underlying patent "Mutant HSP70i to Prevent Autoimmune Disease" (Appl. No. 15/791,609) for Temprian’s platform technology was approved and issued by the USPTO on May 27, 2020.

Read the full story at https://www.prweb.com/releases/temprian_therapeutics_finalist_in_nature_merck_spinoff_2020_competition/prweb17232488.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related medicine news :

1. Actuate Therapeutics Announces Initiation of Additional Clinical Studies for 9-ING-41
2. Eolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation
3. EMulate® Therapeutics Announces Multiple Presentations on the Voyager and Hælo® systems
4. Better Therapeutics Demonstrates Proof of Concept in the Use of Digital Biomarkers to Improve Treatment Outcomes
5. FDA Accepts for Filing the Humanitarian Device Exemption Application For EMulate Therapeutics™ Hælo™ Pediatric System
6. Neutron Therapeutics Installs Europe’s First Accelerator-Based Boron Neutron Capture Therapy (BNCT) Platform – On Track for First Cancer Patient Treatment in 2019
7. Saol Therapeutics Announces CDC has Updated Information Related to Use and Availability of VARIZIG® (Varicella Zoster Immune Globulin [Human])
8. uBiome Receives Patent for Diagnostics and Therapeutics for Endocrine System Conditions
9. uBiome Receives Patent for Diagnostics and Therapeutics for Microbiome Functional Features
10. Madam Therapeutics Closes €1.1 Million Financing Round to Develop Novel Antibiotics Against Drug Resistant Bacteria
11. Symbiomix Therapeutics Receives FDA Approval of Solosec™ (secnidazole) Oral Granules Following Four-Year Collaboration with Catalent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2020)... ... August 11, 2020 , ... Help.org , a trusted ... the Best Rehab Facilities in Greenville, for 2020. The informational guide recognizes the ... , According to recent studies , drug overdose is the leading cause ...
(Date:8/11/2020)... ... 11, 2020 , ... HopSkipDrive , the innovative safe ... Advisory Board: community-centered doctor and public health outcomes expert Dr. NanaEfua B. Afoh-Manin, ... safety evolves with the COVID-19 pandemic, and school districts wrestle with how and ...
(Date:8/7/2020)... ... August 07, 2020 , ... As part of their ... during this past spring, The Bengtson Center team decided to temporarily suspend most in-person ... on an individual basis. With the offices now open again, the leading plastic ...
(Date:8/5/2020)... ... August 05, 2020 , ... ... Learning (SEL) program, has been named to the inaugural list of Best Digital ... , This recognition honors electronic resources that provide enhanced learning and curriculum ...
(Date:8/5/2020)... ... August 05, 2020 , ... Hypoglycemia ... seizures, prolonged length of hospital stay, or even death. A researcher at the ... with Type 2 diabetes to see if the use of continuous glucose monitoring ...
Breaking Medicine News(10 mins):
(Date:8/12/2020)... ... August 12, 2020 , ... As ... offering advice for parents of the more than 1 million U.S. children who ... and adjust to new virtual and modified in-person learning environments. , Virtual ...
(Date:8/11/2020)... ... ... RCare, Inc. (Response Care), creator of advanced nurse call and monitoring solutions, announced ... to new major product offerings and an expanded staff. , RCare’s latest products were ... Deployment Kit (RDK), a portable, wireless nurse call system in a box. ...
(Date:8/7/2020)... ... August 07, 2020 , ... Glewed TV, a leading video-on-demand ... video content, today announced a partnership with award-winning director Charles Mattocks to air ... patients. The first reality TV series of its kind, Eight Days first aired ...
Breaking Medicine Technology: